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Abstract
OnconaseH is a highly cytotoxic amphibian homolog of Ribonuclease A. Here, we describe the construction of circularly
permuted OnconaseH variants by connecting the N- and C-termini of this enzyme with amino acid residues that are
recognized and cleaved by the human immunodeficiency virus protease. Uncleaved circularly permuted OnconaseH variants
are unusually stable, non-cytotoxic and can internalize in human T-lymphocyte Jurkat cells. The structure, stability and
dynamics of an intact and a cleaved circularly permuted OnconaseH variant were determined by Nuclear Magnetic
Resonance spectroscopy and provide valuable insight into the changes in catalytic efficiency caused by the cleavage. The
understanding of the structural environment and the dynamics of the activation process represents a first step toward the
development of more effective drugs for the treatment of diseases related to pathogens expressing a specific protease. By
taking advantage of the protease’s activity to initiate a cytotoxic cascade, this approach is thought to be less susceptible to
known resistance mechanisms.
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Introduction
In Nature, zymogens and limited proteolysis are a common
means to regulate the activity of proteases and of many other
biological processes. This mechanism is based on the control of
enzyme activation rather than inhibition [1]. Inspired by protease
zymogens, Raines and co-workers extended this strategy to bovine
pancreatic ribonuclease (RNase A) by connecting the amino and
carboxyl termini with a peptide segment that caps the active site
and thus acts like a pro-segment of a natural zymogen and inhibits
the native ribonucleolytic activity [2,3,4]. Upon cleavage of this
linker by a specific protease, near-wild type activity of RNase A is
reconstituted. Despite their promise as targetable toxins, RNase A
zymogens still must evade the action of the cytosolic ribonuclease
inhibitor (RI), the natural regulator of ribonucleases in mamma-
lian cells, that binds RNase A and its mammalian homologs with
extremely high affinity (Ki<10215 M).
OnconaseH (ONC), initially named P-30 protein [5] or
ranpirnase, is an amphibian ribonuclease which has much less
ribonuclease activity than its mammalian homologs but is much
more cytotoxic [6,7]. The high cytotoxicity of ONC has been
attributed to a quick internalization process [8,9], its ability to
evade the cytosolic RI [7,10], an unusually high conformational
stability [11,12] and to its ribonucleolytic activity [13,14,15].
Because of its cytotoxicity, ONC became the first ribonuclease to
be assayed in clinical trials and is presently in advanced clinical
trials for the treatment of different types of cancer [16,17].
Further, ONC has been shown to inhibit human immunodefi-
ciency virus 1 (HIV-1) production through the degradation of viral
RNA [9]. Considering the special abilities of ONC, we reasoned
that it would be interesting to construct zymogens of ONC with a
linker sequence that obstructs the active site and encloses a
cleavage site for HIV-1 protease. The first drugs available in the
fight against Acquired Immune Deficiency Syndrome (AIDS) were
nucleoside analogs designed to hamper reverse transcription; later
peptide-based inhibitors aimed to block the action of HIV protease
were developed (for reviews see [18,19]. The combination of both
types of drugs lead to the current highly effective antiretroviral
therapy (HAART) which results in a dramatic reduction of virus
burden with concomitant reduction in symptoms associated with
the disease. Nevertheless, the development of drug resistance is an
increasing problem and therefore new strategies that are less likely
to be circumvented by the virus are needed.
Design and production of ONC-based zymogens would provide
a mechanism to control the ribonucleolytic activity of ONC and
consequently, of its cytotoxicity. Such an ONC zymogen could
specifically target diseased cells that have the protease that
activates the zymogen. Such a strategy could be further explored
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for the development of chemotherapeutics that could evade the
known mechanisms of drug resistance developed by pathogenic
organisms such as those observed for HIV-1 strains whose mutant
proteases do not bind inhibitor compounds.
Here we report on ONC variants that can be cleaved by HIV-1
protease. Rational design has been used to construct and optimize
circularly permuted variants of ONC that include the Gln1Ser
substitution. Although treatment with the HIV-1 protease
successfully cleaves some of the ONC variants, the linker lowers
the catalytic efficiency of the ribonuclease, regardless of whether it
is intact or proteolyzed, and a small increase in activity is observed
upon proteolytic activation. To better understand the principles of
the catalytic activity of our constructs, we have determined the
solution structure of the best cleaved circularly permuted ONC
variant, named ONCFLG, by NMR spectroscopy. The 3D
structure of this circularly permuted ONC variant reveals insight
into its activation and lays the foundation for further exploration of
zymogens as promising tools for the treatment of HIV/AIDS or
related diseases caused by retrovirus or other malignancies
originated by pathogens harboring specific proteases.
Materials and Methods
Design of Circularly Permuted ONC Variants
To aid the design of circularly permuted ONC variants,
structural models were created by modification of the atomic
coordinates of wild type ONC (pdb accession code 1ONC) [20]
and submitting a modeling request to the automated homology
modeling server SWISS-MODEL. The models were optimized by
using the GROMOS 96 implementation of Swiss-PdbViewer [21].
Only the retrieved models that were not distorted and did not
showed global positive energy after minimization were considered
for the development of circularly permuted ONC variants.
Plasmid Construction
Plasmids that direct the production of ONC variants were
constructed by circular permutation using pONC [22] as a
template, following the strategy described by Raines and
coworkers [2]. The detailed procedure and the oligonucleotides
are available in the Supporting Information S1 file.
Production of Circularly Permuted ONC Variants,
ONCQ1S, Wild Type ONC and HIV-1 Protease
Circularly permuted ONC variants and ONCQ1S were
produced and purified essentially as described previously for wild
type ONC [8,23]. Production and kinetic characterization of HIV-
1 protease has been described in detail in the Supporting
Information S1 file.
Calorimetric Conformational Stability Determination
The stability of wild type ONC, ONCQ1S, ONCFL and
ONCFLG was determined by differential scanning calorimetry
(DSC) at the Plataforma de Polimorfisme i Calorimetria from the
Serveis Cientificote`cnics of the Universitat de Barcelona by
means of a VP-DSC equipment from MicroCal (Northampton,
MA, USA). For these measurements, proteins were dissolved in
0.1 M 2-[N-morpholine] ethanesulfonic acid-NaOH (MES-
NaOH) buffer, pH 6.0 at concentrations of 0.15–0.18 mM as
determined by Bradford assay [24], and temperature was
increased from 30 to 110uC using a scan rate of 1 K min21.
Td is the denaturation temperature and corresponds to the
maximum of the DSC peak.
Activation of Circularly Permuted ONC Variants
The activation of the different circularly permuted ONC
variants was assayed with different molar ratios of the HIV-1
protease to variant ranging from 1:5 to 1:100, in buffer composed
of 100 mM sodium acetate/acetic acid, pH 4.7, 300 mM NaCl
and 4 mM EDTA. Aliquots were taken at different times, mixed
with SDS-PAGE loading buffer and stored at 220u until analysis
by electrophoresis. Progress of the activation reactions was
quantified using the Imaging System FluorChemH SP (Alpha
Innotech, San Leandro, CA, USA).
Enzymatic Activity of Circularly Permuted ONC Variants
The ribonucleolytic activity of ONCFL and ONCFLG variants
before and after cleavage was measured with the fluorogenic
substrate 6-FAM-dArUdAdA-6-TAMRA [25] using a Lambda
LS50 fluorescence spectrometer (Perkin-Elmer, Waltham, MA,
USA) equipped with a thermostat and sample stirring. Each
measurement was repeated at least three times and values in
Table 1 are expressed as the mean 6SD.
Cytotoxicity of Circularly Permuted ONC Variants
The cytotoxicity of wild type ONC, ONCQ1S and circularly
permuted ONCFL and ONCFLG variants was assayed on human
T-lymphocytes Jurkat cells by measuring the IC50 values as
described previously [8]. The IC50 values represent the concen-
tration of the assayed enzyme required to inhibit cell proliferation
by 50%. The results for a single experiment are the average of
three determinations, and the experiments were repeated inde-
pendently three times each (Table 1).
Internalization of ONCFLG-Cys Variant
The Ser72Cys substitution was introduced by QuikChangeTM
(Stratagene, La Jolla, CA) site-directed mutagenesis at the C-
terminus of ONCFLG variant. This Cys was conjugated to the
fluorochrome Alexa FluorH 488 C5 maleimide (Molecular Probes,
Life Technologies, Carlsbad, CA, USA) essentially as recom-
mended by the manufacturer. Jurkat cells were incubated with the
labeled variant for known times, and in all samples, cell nuclei and
membranes were counterstained with Hoechst 33342 (Molecular
Probes, Eugene, OR, USA) and DiI, respectively. Considering that
Jurkat cells are an immortalized line of T lymphocytes, a common
host of HIV infection, they are relevant for studies aiming to
develop improved AIDS therapeutics. Internalization was visual-
ized with a Leica TCS SP2 AOBS laser scanning confocal
microscope at the Servei de Microsco`pia de la Universitat
Auto`noma de Barcelona.
Solution Structure, Dynamics and Conformational
Stability Determined by NMR
The solution structure of ONCFLG (pdb: 2LT5) at pH 5.2
35uC was determined on the basis of NOE distance constraints
and backbone torsional angle restrictions. 1H-2H exchange to
monitored conformational stability was monitored by a series of
1H-15N HSQC experiments. The 1H-15N internuclear NOE was
measured to gauge the residue-level dynamics. The complete
procedural details of all these experiments as well as the
interaction of ONCFLG with the d(UGG)3 substrate analog and
the determination of a structural model of the cleaved form of
ONCFLG are given in the Supporting Information S1 file.
Accession Numbers
The 1H, 13C and 15N resonance chemical shift assignments of
ONCFLG variant have been deposited at the BMRB with the
3D Structure of a Circularly Permuted ONC Variant
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deposition number 17973 and the coordinates are available at the
Protein Data Bank with the accession code 2LT5.
Results
Design, Production and Activation of ONCYP Variant
When designing ONCYP, two features of ONC that might
influence the activity, namely, the overall stability and the
cytotoxicity, were taken into account. First, the N-terminal Gln1
of ONC, which spontaneously cyclizes to form a pyroglutamyl
(Pyr) residue [13,20], was replaced by Ser, which is the substitution
that retained the highest catalytic efficiency and cytotoxicity
among those surveyed [14]. Second, ONC presents a C87/C104
disulfide bond that tethers the C- terminal Cys104 to a central b-
strand, and thus sequesters it from the N-terminus [20]. Analysis of
the crystal structure of ONC (pdb code 1ONC) reveals that the
distance between the N- and C-terminal residues is 18 A´. This
distance could be covered by as few as 5 residues in a fully
extended conformation. Our simulations, however, suggested that
sequences of 14 amino acids or longer would be required to
connect the native termini and encode the HIV protease
recognition motif without perturbing the overall structure.
The selection of the new termini Arg73/Ser72 was based on the
solvent accessibility of these residues, which form a loop
connecting strands b4 and b5 of ONC. We had previously shown
that this loop is able to accommodate a Ser72Cys substitution,
which we used to fluorescently label ONC and follow its cellular
internalization [8]. Moreover, in many onconase homologs, e.g.
Eosinophil Cationic Protein [26] this loop is much longer. This
fact, and the observation of flexibility in this loop as judged by
normal mode analysis and conformational changes upon ligand
binding or temperature changes [15] suggests that this loop will be
tolerant to modification. In contrast, two other solvent exposed
loops, that connect the last two b-strands or the third and second
to last b–strands in wild type onconase, frequently contain cis
Prolines in onconase homologs such as RNase A and are much less
tolerant to mutation. Finally, thanks to the disulfide bonds 19–68
and 30–75 in wild type onconase, the new free N- and C-termini
will still be effectively tethered to the rest of the protein in
circularly permuted variants despite the rupture of the protein
chain between residues 72 and 73. The X-ray structure of wild
type ONC and a model of ONCFLG (generated as described in
Material and Methods section) highlighting the old and new
termini are shown in Figure 1 together with the lengths and the
sequences of the different linkers used in this work and the
sequence numbering of ONC and the ONCFLG variant.
In the ONCYP variant, the native termini, Cys104 and Ser1,
are connected by the octapeptide sequence SQNY*PIVQ, which
corresponds to the naturally occurring Pr55gag p17/p24 cleavage
site for HIV-1 protease where Tyr*Pro is the cleaved peptide bond
[27]. This sequence is also present in the substrate used to verify
the protease’s activity following its purification (see Supporting
Information S1). The residues flanking the recognition sequence
of HIV-1 protease (Figure 1) were intended to link the protein
ends while providing flexibility and solubility due to their small
and/or polar side-chains. After expression in E. coli BL21 (DE3) as
inclusion bodies, the ONCYP variant was subjected to oxidative
refolding in vitro and purified with a yield exceeding 25 mg/L of
culture. Protein purity and homogeneity were confirmed by SDS-
PAGE and the molecular mass confirmed by MALDI-TOF mass
spectrometry (Table S1).
The cleavage of the ONCYP by HIV-protease, was assayed using
different molar protease:ONC variant ratios and distinct incubation
times. As shown in Figure 2, the cleavage of ONCYP rapidly
reached a plateau approximately 4 hours after the addition of
protease. Even when a 1:5 molar protease:ONC variant ratio was
used, further incubation (up to 30 hours) did not result in additional
cleavage, and the final yield of cleaved variant was only 10%.
Circularly Permuted Variant Cleavage Optimization
With the aim of improving protease action, new linkers (Figure1)
were designed based on two principles: i) flexibility and linker length
were increased to favor the accessibility of the protease and ii) a
different protease recognition motif sequence was employed. An
additional Gly residue was added either on one side (ONCYPG1) or
the other (ONCYPG2) or on both sides (ONCYPGG) of the cleaved
bond (Figure 1). Secondly, we choose GSGIF*LETSL as a new
target sequence [28]. Because the 14 residue linker of ONCYP
resulted in poor cleavage, ONCFL and ONCFLG variants were
designed with linkers of 15 and 16 residues, respectively. As shown in
Figure 1, ONCFLG contains an additional Gly residue on the
amino side of the bond to be cleaved.
The activity of HIV-1 protease on these new ONC variants was
also assayed. As shown in Figure 2, after 30 hours of incubation
with a 1:5 protease:ONC variant ratio, 38%, 32% and 43% of
ONCYPG1, ONCYPG2 and ONCYPGG, respectively, were
cleaved. Thus, elongation of the linker sequence results in 3–4 fold
increase in cleavage relative to the original ONCYP variant
containing the matrix/capsid (MA/CA) cleavage site of the HIV-1
Gag-Pol polyproteins. More interestingly, ONCFL and ONCFLG
variants were completely cleaved at shorter incubation times
(Figure 2A) and using molar ratios of HIV-1 protease:ONC
variant as low as 1:100. These results indicate that linkers based on
the amino acid sequence GSGIF*LETSL are more efficiently
hydrolyzed by HIV-1 protease than those based on the MA/CA
site SQNY*PIVQ.
Table 1. Analysis of the stability and functionality of ONC variants.
Td(6C)a IC50 (mM)b uncleaved kcat/KM uncleavedc kcat/KM cleavedc
kcat/KM cleaved/kcat/
KM uncleaved
wild type ONC 87.560.3 0.4660.03 – 7.3160.11 –
ONCQ1S 84.760.5 4.060.8 – 2.6060.08 –
ONCFL 80.960.1 28.260.9 0.3760.04 0.4760.06 1.27
ONCFLG 80.560.1 862 0.9560.16 1.1060.04 1.16
aTd were determined in 0.1 M MES-NaOH buffer, pH 6.0 by DSC as described in Material and Methods.
bIC50 (6SD) values were determined using the CellTiter96H cell viability assay as described in Material and Methods.
cUnits of catalytic efficiency, kcat/KM, are 10
2 M21s21. Values of kcat/KM were determined for catalysis of 6-FAM-dArUdAdA-6-TAMRA cleavage at 25uC in 0.1 M MES-NaOH
buffer, pH 6.0, containing 0.1 M NaCl [43].
doi:10.1371/journal.pone.0054568.t001
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Catalytic Efficiency of the Intact and Cleaved Circularly
Permuted Variants
Next, the functionality of ONCFL and ONCFLG variants was
determined by measuring the ribonucleolytic activity on the
fluorogenic substrate 6-FAM-dArUdAdA-6-TAMRA of both the
precursor and the cleaved form of each variant. As shown in
Table 1, treatment with HIV-1 protease marginally increased the
ability of both variants to catalyze the cleavage of the tetranucle-
otide substrate by approximately 1.27 and 1.16-fold for ONCFL
and ONCFLG, respectively. Therefore, the low catalytic efficiency
Figure 1. Zymogen model and linker sequences. (A) 3D structure of ONC (pdb accession code, 1ONC). (B) Structural model of the ONCFL
variant generated using the automated homology modeling server SWISS-MODEL and energy minimized with the GROMOS 96 implementation of
Swiss-PdbViewer [21]. The amino and carboxyl termini created by circular permutation and the residues that constitute the cleavage site are
represented using red sticks. Both figures were drawn with PyMOL (http://pymol.sourceforge.net/). Note that the linker segment was predicted to be
helical in this model, but its structural characterization by NMR shows that it is disordered. (C) Scheme of the primary sequence of the linkers used in
the design and construction of the different zymogens. Native carboxyl and amino residues of ONC are in bold and Gly residues used to elongate the
linker are in red. The HIV-1 protease recognition sequence is underlined and Y*P and F*L indicate the hydrolyzed peptide bonds. (D) Alignment of
ONC and ONCFLG amino acid sequences showing the secondary structure representation for ONC. The residues that compose the FLG linker
connecting Ser1 and Cys104 are in bold and underlined.
doi:10.1371/journal.pone.0054568.g001
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Figure 2. Cleavage of circularly permuted ONC variants by HIV-1 protease. (A) Cleavage measured at different times after addition of HIV-1
protease at a molar ratio (protease:variant) of 1:5 for YP and 1:100 for FL variants and analysis by Coomasie-stained SDS-PAGE under reducing
conditions. For all the gels, lane M corresponds to molecular mass standards: 15, 10 and 4 kDa. For variants ONCYP, ONCYPG1, ONCYPG2 and
ONCYPGG, lanes 1 to 7 correspond to samples taken 0, 1, 2, 4, 6, 20 and 30 h after protease addition. For ONCFL (lanes 1–8), samples were taken at
0 min, 15 min, 30 min, 45 min, 1 h, 5 h, 20 h and 30 h and for ONCFLG (lanes 1–8), at 0 min, 15 min, 30 min, 45 min, 1 h, 1.30 h, 2 h, 20 h and 30 h.
(B) Time-course of the activation of the different variants followed by quantification of the disappearance of the variant band using the Imaging
System FluorChemH SP (Alpha Innotech, San Leandro, CA, USA). Legends: ONCYP (N); ONCYPG1 (.); ONCYPG2 ( =); ONCYPGG (#); ONCFL (&);
ONCFLG (%).
doi:10.1371/journal.pone.0054568.g002
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observed for the intact and cleaved variants relative to the Q1S
variant is not the result of the intact linker, but rather the
additional amino acids at the termini, regardless of whether they
are connected or not.
Cytotoxicity of Circularly Permuted ONC Variants
The cytotoxicity of uncleaved ONCFL and ONCFLG variants
was compared to wild type ONC and ONCQ1S by measuring
their IC50 values on human T-lymphocytes Jurkat cells. Both
variants were less toxic to Jurkat cells than the parent enzymes and
their IC50 values increased between 2- and 70-fold in comparison
to the IC50 values of ONCQ1S and ONC, respectively (Table 1).
These results indicate that these variants lose some of the
cytotoxicity of the wild type enzyme.
Internalization of ONCFLG-Cys Variant
ONC internalization into K562 erythroleukemic cells has been
shown to proceed rapidly and maximum cell labeling was achieved
after only 45 min [29]. To evaluate the internalization capability
of circularly permuted ONC variants, ONCFLG variant in which
the C-terminal Ser was replaced by Cys, was fluorescently labeled
by conjugation with Alexa FluorH 488 C5 maleimide. Alexa-
labeled ONCFLG variant was incubated with Jurkat cells and
internalization was monitored at different times in samples with
counterstained cell nuclei and membranes. As shown in Figure
S1, labeled variant is detected inside the cells after 3–6 h and
internalization increased up to 12 h after incubation using
concentration as low as 2 mM of labeled variant.
Structure of ONCFLG Variant
The superposition of the 20 conformers of the best cleaved
variant, ONCFLG, determined by NMR is shown in Figure 3.
These structures, obtained utilizing the calculation protocol
described in the Material and Methods section, satisfy the
structural constraints and have low potential energies (Table 2).
The structure is well defined, maintains the same tertiary structure
shown by other members of the RNase A superfamily and is
particularly similar to that of wild type ONC [20,30], and also to
variants prepared by site-directed mutagenesis [31,32] and
cytotoxic bullfrog ribonucleases [33,34]. The three a-helices: a1,
Leu52-His58, a2, Ile70-Ser72 and a3, Pro89-Ala94 (variant
numbering) match quite well with the helices present in wild type
ONC consisting of residues Trp3-His10, Cys19-Ile22, Pro41-
Lys49 (wild type numbering). The b-strands b5, Tyr5-Asn12, b6,
Phe14-Cys18, b7, Pro23-Val29, b0, Ile59-Thr60, b2, Lys81-
Tyr86, b3, Lys103-Thr107 and b4, Phe111-Val118 are also
equivalent to those of native ONC. A detailed inspection of
ONCFLG structure shows that there is a subtle local rearrange-
ment near Cys18-Cys96 respect to wild type ONC. In ONCFLG,
there is an increase of about 1A˚ between these cysteines’ Ca -Ca
distance that is probably related with the absence of the 310-helix
motif following a3 present in wild type ONC (Figure S2).
It is interesting that the linker segment Gly33-Gly48 designed to
block the access to the active site of the ONCFLG variant does not
adopt a regular secondary structure. The backbone RMSD of this
segment is 1.5 A˚ in contrast to 0.2 A˚ shown by the rest of the
protein (Table 2). This region extends beyond of the protein core
occupying the concave face of the common RNase kidney-shaped
structure. In this way, access to the active site cleft containing the
catalytic triad (His25, His58 and Lys79) that is characteristic of the
RNase A superfamily and also, Ser49 (Pyr1 in wild type) and
Lys57, exclusive of frog ribonucleases, may be hindered by this
flexible linker, which may act as a ‘‘steric bristle’’ [35].
A closer look at the structure provides information about the
active site residues and their relationship to the ribonucleolytic
activity. Whereas all the residues belonging to B1 (Lys81, Thr83,
Asp115 and Phe26) and B2 (Thr17 and Glu19) subsites show the
same orientation as the equivalent residues in the crystal structure
of wild type ONC (1ONC) [20] or ONC-d(AUGA) complex (2I5S)
[31], remarkable differences are observed for active site (or P1
subsite) residues. Ser49 Oc, that should replace the wild type N-
terminal Pyr1 Oe, is not hydrogen-bonded to Lys57 Nj (Lys9 in
wild type ONC) and consequently a high mobility is observed for
Lys57 side chain. Lys79 has been proposed to work together with
Lys57 to stabilize negative charge buildup on a nonbridging
phosphoryl oxygen during catalysis [13,20,31]. However, Lys79
protrudes out of the ONCFLG structure, instead of pointing
towards the active site cleft as does its equivalent Lys31 in wild
type ONC (Figure 4). As a consequence of the movement of
Lys57, His58 appears to oscillate up and down in the ONCFLG
structure between two different conformations which differ by
approximately 90u in the occupancy of the imidazole ring. The
imidazole ring of His25, in contrast, occupies an ensemble of
conformations midway between those of the His97A conformation
observed in the ONC-d(AUGA) complex (2I5S) and the His97B
conformation shown in wild type ONC (1ONC) structure
(Figure 4B and 4C).
Interaction of ONCFLG with a Substrate Analog
To further characterize the active site of ONCFLG, we studied
its interaction with an uncleavable substrate analog, d(UGG)3.
The complete details of these experiments are provided in the
Supporting Information S1 file. In summary, ONCFLG and
d(UGG)3 combine immediately at pH,7 to form an insoluble
precipitate, but remain dissolved about pH 7 with little evidence
for specific binding. The formation of the precipitate at low pH is
likely to be driven by relatively nonspecific electrostatic interac-
tions. At alkaline pH, no unambiguous intermolecular NOEs
between d(UGG)3 and ONCFLG could be assigned, no changes in
the tautomeric states of the His residues were observed and only
two significant chemical shift changes were detected. Therefore, at
alkaline pH the binding of ONCFLG and d(UGG)3 appears to be
weak to insignificant.
Structure of the Cleaved ONCFLG Variant
To determine the structural changes in ONCFLG provoked by
HIV-1 cleavage, the resonance assignments of the cleaved variant
were obtained following the same methodologies used for the
uncleaved protein [36]. Figure 5A shows a comparison of the
1H-15NHSQC of the cleaved and uncleaved forms of ONCFLG.
As expected, the HN signal corresponding to Leu41 is absent in
the cleaved form, as hydrolysis by the HIV-1 protease of the
Phe40-Leu41 amide bond converts the CO-HN group into –
COO– and H3N
+–. Most of the HN signals retain their chemical
shifts upon cleavage, and the most affected ones belong to Phe40
and Glu42, which flank the HIV-1 protease cleavage site. The
differences of the 13Ca and 13Cb chemical shifts (Dd) between the
cleaved and uncleaved ONCFLG variant are plotted in
Figure 5B. Most Dd values are small (,0.1 ppm) except for the
segment Phe40-Asp50 located close to the hydrolyzed peptide
bond. These data clearly point to the conservation of the global
fold, accompanied by structural differences in the linker segment
after cleavage. Moreover, the analysis of the NOESY spectra
allowed us to identify similar sets of short and long range NOEs in
the structured regions of the cleaved and uncleaved variant. This
corroborates that their 3D structures are very similar. On the basis
of these data, a structural model for the cleaved ONCFLG variant
3D Structure of a Circularly Permuted ONC Variant
PLOS ONE | www.plosone.org 6 January 2013 | Volume 8 | Issue 1 | e54568
was built (Figure 5C). The most remarkable change is the
increased number of conformations available to the segments
bordering the cleavage site.
ONCFLG Variant Dynamics
To elucidate the local backbone flexibility of ONCFLG variant
in the ns-ps time-scale, we have measured the heteronuclear NOEs
(Figure 6A). Most residues show NOE ratio values close to the
highest value (0.85) expected theoretically for rigid 15N-1H vectors,
in agreement with previously reported results in ONC and its
variants [33,37]. The N- and C-termini are more flexible with
NOE ratio values ranging from about 0.5 to 0.6. The hetero-
nuclear NOE values show that the 16 residue segment inserted to
connect the wild type termini is the most flexible part of the
molecule. In the uncleaved form, residues Ser34 to Gly48 show an
average NOE ratio value of 0.38. This suggests that this region
behaves as a flexible loop with fast motions in the ns-ps time scale
characteristic of an unstructured region. Remarkably, this
flexibility is substantially increased in the cleaved form with
Gly38 to Ser44 showing negative NOE values. Thus, the
conformational freedom of the new termini is like that of short
unstructured peptides.
Conformational Stability of the Circularly Permuted ONC
Variants
As shown in Table 1, the midpoint of thermal unfolding (Td) of
the ONCFL (80.9uC) and ONCFLG (80.5uC) variants as
determined by DSC, are considerably higher than the physiolog-
ical temperature (37uC) and comparable to the values determined
previously for ONCQ1S and wild type ONC [38]. This ensures
that these variants are stable enough to be used in vitro and in vivo
under physiological conditions.
Moreover, the residue-level conformational stability of
ONCFLG in the uncleaved and cleaved forms, DGHX, was
measured by 1H-2H exchange monitored by NMR. The most
protected and stable amide groups (Figure 6B) are located in the
secondary structure regions, mainly the b-sheets and the first and
third a-helices. Relative to most proteins, including RNase A [39],
the average DGHX of these secondary structural elements is high,
which reflects the extraordinary conformational stability of
ONCFLG. Remarkably, the inserted segment (residues 33–48)
shows no measureable protection against 1H-2H exchange under
these conditions. The HN protons of the second helix are also
unprotected as was described for wild type ONC and variants
[37]. The same helix has been observed to have a relatively low
stability in RNase A and human RNase 3 (eosinophil cationic
protein) [26]. The geometry of the H-bonds formed by this helix is
suboptimal in these proteins. Upon cleavage, the DGHX values
become about 1.7 kcal/mol lower on average. Assuming that the
dependence of the free energy of stability on Td observed for wild
type ONC [29] holds for ONCFLG, we calculate that the cleavage
of ONCFLG would lower its Td about 6.6uC to 73.9uC. This Td is
still far above 37uC, so cleaved ONCFLG will be stably folded at
physiological temperatures (Figure 6C).
Discussion
To create a ribonuclease zymogen [2] the bridge connecting the
N- and C-termini of the native enzyme must extend over and
block access to the active site. The zymogen is activated when a
specific protease recognizes and cleaves a specific motif within the
bridge. Therefore, the bridge segment must be long enough to
connect the termini without inducing strain and to encode the
protease recognition motif, but short enough to effectively fill the
active site groove to prevent the RNA substrate from binding the
uncleaved zymogen.
Figure 3. 3D structure of ONCFLG by NMR. (A) Backbone superposition of the 20 lowest energy conformers of ONCFLG. The disordered linker
segment (Gly33-Gly48) is represented in orange and the rest of the protein backbone sequence in blue except for the a-helices which are in red. The
views are rotated 180u with respect to each other. (B) Ribbon drawing of a representative conformer of the energy-minimized family of ONCFLG
variant structures. Colors and the orientation are the same as in (A). This figure was generated by VMD [41].
doi:10.1371/journal.pone.0054568.g003
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The initial designed circularly permuted ONC variant,
ONCYP, was not properly cleaved by HIV-1 protease
(Figure 2). We reasoned that although the zymogen design
satisfied the steric requirements as deduced by the high yield of
in vitro refolded protein, the accessibility of the protease might
somehow be impeded. Consequently, ONCYPG1, ONCYPG2
and ONCYPGG were designed to elongate the linker and increase
its flexibility in order to facilitate the protease recognition and
catalysis. On the other hand, Beck and co-workers [28] had
reported that the peptide substrate GSGIF*LETSL identified from
a phage display library, was cleaved 60 times more efficiently than
the MA/CA-based control phage with the sequence SGVSQNY*-
PIVQVL. Therefore, two additional variants, ONCFL and
ONCFLG, were constructed to assay this alternative recognition
sequence. When comparing the activation of the different variants
as a function of the linker length, it was revealed that the longer
the linker, the more efficient was the cleavage by the protease
(Figure 2B). As shown in the Results section, the new variants
comprising the Y*P cleavage site only improved the final yield to
3–4 fold, compared to ONCYP, while ONCFL and ONCFLG
were successfully cleaved by the protease (Figure 2A and 2B).
Besides, the ONCFLG variant is more rapidly cleaved than
ONCFL which could be explained by a facilitated accessibility of
the protease to the ONCFLG scissile bond due to the additional
Gly residue (Figure S3). Thus, the differences in the cleavage
yields among the ONC variants are similar to the results for
different HIV-1 protease substrates reported previously [28].
Therefore, the affinity for a particular amino acid sequence seems
to be the main reason underlying the differences in cleavage
observed between the YP- and FL-variants. Nevertheless, other
factors such as interaction of the linker with the remainder of the
protein, the linkers conformation and the orientation of the
residues near the scissile bond could also affect the final efficiency
of the variant cleavage although in a lesser extent.
To be effective, the intact ONC zymogens should have low
enzymatic activity before activation and a substantial increase in
the catalytic efficiency should be observed after cleavage by the
protease. Here, the enzymatic activity and cytotoxicity of the
variants was determined only for those that could be completely
cleaved, ONCFL and ONCFLG. Both the ONCFL and
ONCFLG uncleaved variants showed low ribonucleolytic activity
and slight cytotoxicity against human T-lymphocytes Jurkat cells
Table 2. Structural Statistics of the 20 best NMR Structures of the ONCFLG.
NOE Distance and Dihedral Constraints
Nu short-range distances (|i–j|#1) 1059
Nu medium-range distances (1,|i–j|,5) 288
Nu long-range distance (|i–j|$5) 678
Nu restraints from S-S bonds 24
Nu angular restraints (Q,y) 149
Nu total restraints 2198
Nu restrictions/residue 18.3
Structure Calculation
CYANA target function value (min, mean, max) 1.54, 1.69, 1.96
Maximum distance violation (A˚) (min, mean, max) 0.12, 0.20, 0.47
Maximum dihedral angle violation (u) (min, mean, max) 2.32, 3.58, 9.51
Average AMBER energy (kcal/mol) 23926
Average AMBER Electrostatic energy (kcal/mol) 27769
RMSD bond lengths from ideal geometry (A˚) 0.0160.001
RMSD angles from ideal geometry (u) 2.1760.01
Averaged pairwaise RMSD (A˚) (backbone, heavy atoms)
Global (1–120) 0.860.3 1.360.3
Structured region (1–32, 49–120) 0.3260.07 0.9660.07
Unstructured linker (33–48) 1.560.6 2.160.8
Secondary structure (helices and sheets) 0.2560.06 0.8460.08
a-helices (51–58, 70–72, 90–94) 0.2160.06 1.060.2
b-sheets (5–12, 14–18, 23–29, 59–60, 81–86, 103–107, 111–118) 0.2360.05 0.7560.09
Ramachandran Plot Analysis (%)
Most favored regions 74.9
Additional allowed regions 24.7
Generously allowed regions 0.0
Disallowed regions 0.0
doi:10.1371/journal.pone.0054568.t002
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which are desirable characteristics of a zymogen. However, only a
minor increase in the catalytic activity of 1.27- and 1.16-fold for
ONCFL and ONCFLG, respectively, is observed following HIV-1
protease cleavage. In addition, in these initial studies we have
shown by confocal laser scanning microscopy that Alexa-labeled
ONCFLG efficiently penetrates Jurkat cells. To better understand
Figure 4. Superposition of different conformations of the active site residues. A. Comparison of different conformations of ONCFLG P1
subsite residues shown in different colors with the homologous residues from ONC-d(AUGA) in white. Letters G, R, P and U stand for guanine, ribose,
phosphate and uracil, respectively. B. ONCFLG conformations are shown in CPK color while wild type ONC (1ONC.pdb) and ONC-d(AUGA) complex
(2I5S.pdb) are shown in lime and in yellow, respectively. C. Same as B except that all the residues are drawn in CPK color to show how Nd1 and Ne2
from His25 exchange their position through the rotation around the x2 dihedral angle, midway between those of His97A conformation observed in
the ONC-d(AUGA) complex and the His97B conformation shown in wild type ONC structure. Structural alignments and figures B and C and were
generated using VMD (Humphrey, Dalke et al. 1996), whereas figure A was drawn using Swiss-PdbViewer (Guex and Peitsch 1997).
doi:10.1371/journal.pone.0054568.g004
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the cleavage process and explain the low increase in activity
following cleavage, we solved the 3D structure of ONCFLG
zymogen by heteronuclear NMR spectroscopy. The well-defined
structure we obtained is closely similar to that of wild type ONC,
except the linker segment Gly33-Gly48 does not adopt any regular
secondary structure and shows high structural diversity. In
addition, based on the measurement of heteronuclear NOEs, this
linker segment is also the most dynamic region of the molecule in
the uncleaved form. The conformational flexibility exhibited by
the linker, together with the accessibility of the Phe40-Leu41
residues that contain the scissile bond (Figure S3), explains the
rapid cleavage of ONCFLG variant. After cleavage, the new
termini show NOE values characteristic of unstructured peptides
with a high degree of conformational freedom.
The residue-level hydrogen exchange measurements corrobo-
rate the extraordinary stability of ONCFLG as determined by
DSC. The remarkable stability of the ONC variants is somewhat
surprising considering that the N- and C-termini have been
permuted. No measurable protection against 1H-2H exchange was
observed for the intact or cleaved linker segment; this is consistent
with the lack of well-defined secondary structure and highly
dynamic behavior indicated other NMR results. Upon cleavage,
the DGHX values throughout the protein become slightly lower on
average which suggests that interactions between the linker and
the protein core make modest contributions to the latter’s stability.
Comparison of the ONCFLG structure with the available wild
type ONC structures also sheds light on the variation in
ribonucleolytic activity observed between the uncleaved and
cleaved forms. Although there are no differences in occupancy
for residues belonging to the B1 and B2 subsites, remarkable
changes are observed for the catalytic residues. Raines and co-
workers [13] showed that the Pyr1 to Ala substitution resulted in a
20-fold decrease in ONC’s ribonucleolytic activity and suggested
that the loss of the Pyr1 Oe-Lys9 Nj hydrogen bond would
provide Lys9 with rotational freedom, reducing catalysis. In
addition, replacing either Lys9 or Lys31 with an Ala decreased the
value of kcat/KM by 10
3-fold. The catalytic activity of the double
mutant was below the sensitivity limit of the assay. These results
lead to the conclusion that both Lys9 and Lys31 contribute to the
stabilization of the transition state. This ONCFLG structure
reveals that the loss of this hydrogen bond is responsible for the
conformational freedom observed for Lys57 side chain (Lys9 in
wild type ONC) and corroborates that the function of Pyr1 in wild
type ONC is to position Lys9 appropriately for catalysis. More
precisely the Lys79 side chain (Lys31 in wild type ONC) turns
away from the main body of ONCFLG (Figure 4A). In
ONCFLG, the mobility of His58 increases and the imidazole
ring of His25 can rotate about the x2 dihedral angle without
adopting the A or B conformations observed in the ONC-
d(AUGA) complex (2I5S) and in the wild type ONC (1ONC)
structure, respectively (Figure 4B and 4C). These changes are
likely to be consequences of the movements of Lys57 and the
presence of the bridge that connects the native N- and C- termini.
The catalytic efficiency of the ONCQ1S variant, that also likely
lacks the aforementioned hydrogen bond between Pyr1 Oe and
Figure 5. NMR data and structural model of the cleaved
ONCFLG variant. (A) Region of the 2D 1H-15N HSQC spectra of the 15N
labeled ONCFLG variant (black) superimposed onto that of cleaved form
(red). Spectra were recorded at 800 MHz, 35uC and pH 5.2. Represen-
tative 1H-15N correlations of the uncleaved form are labeled and black
arrows indicate the corresponding shifted signals in the cleaved
ONCFLG form. (B) Comparison of the 13Caand 13Cb chemical shift
values for the uncleaved and cleaved forms of ONCFLG variant. Dd
values were obtained from the difference between the reported
uncleaved (BMRB nu: 17973) and cleaved ONCFLG forms values (Dd= d
uncleaved – d cleaved). The arrow shows the position of the hydrolyzed
peptide bond, and the linker segment, Gly33-Gly48, within the dashed
lines. (C) Structural model of the cleaved ONCFLG form. The cleaved
linker segment (Gly33-Gly48) is represented in dark green and the rest
of the protein backbone sequence in dark yellow. The active site
histidines are in light green. This figure was generated by MOLMOL [42].
doi:10.1371/journal.pone.0054568.g005
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Lys57 Nj, is about 3-fold lower than that of wild type ONC while
the kcat/KM values of ONCFL and ONCFLG are 20- and 7-fold
lower, respectively. Therefore, the intact linker directly contributes
to lower the catalytic efficiency of ONCFLG variant by 2-fold and
that of ONCFL to 6-fold, approximately. Taken together, all these
structural characteristics account reasonably well for ONCFLGs
low ribonucleolytic activity.
The structural model for the cleaved ONCFLG (Figure 5)
reveals that the linker segments may adopt a higher number of
conformations following hydrolysis. The movement of these
segments could sterically obstruct the substrate’s approach to the
active site, increase the KM, and worsen the already poor
nucleotide-binding affinity that has been proposed to account in
large measure for the low ribonucleolytic efficiency of ONC
[13,31]. This effect, together with the alterations in the active site
residues in the uncleaved form described above, most of which
remain in the cleaved form, could be the basis of the low catalytic
activities of the cleaved circularly permuted ONC variants and
explain why their ribonucleolytic activities are not as high as that
of ONCQ1S.
Conclusions
In this work we have designed and optimized circularly
permuted ONC variants that are efficiently cleaved by the HIV-
1 protease. However, properly cleaved ONC-FL variants showed
marginal activation and both activity and cytotoxicity were
diminished due to circular permutation. Also, we have solved
the three-dimensional structure of ONCFLG. The structural data
reported herein for ONCFLG lay the groundwork for the future
optimization of zymogens via the redesign of linker length and
sequence to better position the hydrogen bond acceptor group to
fix the Nj of Lys57, insertion of additional substitutions such as
Met28Leu [40] aimed at increasing the catalytic efficiency or, the
design of additional protease cleavage sites within the linker to
diminish the steric hindrance of the segments following cleavage.
Therefore, the creation of successful zymogens based on ONC
would represent a new versatile option to manage the enzymatic
activity of this enzyme and target its toxicity to a cell in a specific
diseased state. ONC-based zymogens activated by microbial or
viral proteases could extend the therapeutic utility of ONC to
maladies other than cancer and represent a strategy to avoid
known mechanisms of pathogenic resistance.
Supporting Information
Figure S1 Internalization of ONCFLG-Cys variant. Un-
cleaved ONCFLG-Cys variant, (2 mM) labeled with Alexa 488,
was incubated with Jurkat cells for known times, and cells were
then washed with PBS three times prior visualization. In all
samples, cell nuclei and membranes were counterstained with
Hoechst and DiI, respectively, for 10 min before washing.
Internalization was visualized with a Leica TCS SP2 AOBS laser
scanning confocal microscope.
(TIF)
Figure S2 Comparison of homologous disulfide bonds
from ONCFLG variant and wild type ONC. Comparison of
homologous Cys18-Cys96 and Cys48-Cys90 disulfide bonds
connecting b-strand b6 and a-helix a3 and Cys15-Cys32 and
Cys87-Cys104 disulfide bonds connecting b-strand b6 and b-
strand b7 in ONCFLG variant and wild type ONC (1ONC.pdb),
respectively. Different conformations from ONCFLG variant
Cys18-Cys96 and Cys15-Cys32 disulfides are shown in CPK
colors and wild type Cys48-Cys90 and Cys87-Cys104 disulfides
Figure 6. Dynamics and conformational stability of the
ONCFLG variant forms. (A) The 1H-15N NOE ratio for the uncleaved
(gray) and cleaved ONCFLG forms (black) as a function of the sequence
number. Lines connecting gray or black squares boxes are used to
guide the eye. (B) and (C) DGHX values obtained by NMR-monitored
1H-2H exchange of the uncleaved (B) and cleaved (C) forms of the
ONCFLG as a function of the sequence number. Grey bars represent the
upper limits for fast exchanging groups, black bars show experimentally
measured values and triangles indicate the estimated lower limit for
slow exchanging groups. The secondary structure is represented on the
top of each panel, b-strands as gray arrows and a-helices as ovals.
doi:10.1371/journal.pone.0054568.g006
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are shown in magenta. This representation was generated using
VMD [41].
(TIF)
Figure S3 Structure of the ONCFLG variant showing the
linker region, active site residues and disulfide bonds.
The different conformations of the linker region Gly33-Gly38 are
shown in orange while the rest of the molecule is shown in grey
ribbon. Phe40-Leu41, that constitute the scissile bond are shown
in red, Ser49, Lys57 and Phe26 are colored in blue and His58,
Lys79 and His25 are in purple. This representation was generated
using VMD [41].
(TIF)
Table S1 Theoretical and experimental molecular
masses of the proteins used in this work.
(DOCX)
Supporting Information S1 Includes supplementary ma-
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